Hemlibra for mild hemophilia A patients
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial studies Hemlibra (emicizumab) in people with mild congenital hemophilia A to see how well it works and what safety issues may occur. It may help reduce bleeding in patients who meet the study’s specific health and safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male and between ages 5 and 45
- You must have mild congenital hemophilia A (baseline FVIII between 5% and 30%) and no FVIII inhibitor history
- Your BMI must be under 30
- You need recent records of bleeding episodes and any bleeding treatments used in the 12 months before joining
- You must be able to attend scheduled visits and complete bleed logs/questionnaires/activity tracking during the study
- You must pass basic liver, kidney, and blood test thresholds at screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two low-dose medicines to prevent bleeding episodes in people with severe hemophilia A: a newer medicine (emicizumab) versus the standard factor VIII treatment. It may help find a more convenient or effective way to reduce bleeding.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
This trial tests a new gene therapy (REGV131-LNP1265) that aims to let your body produce its own factor IX, reducing or stopping the need for regular infusions. It is for children and adults with severe hemophilia B who are already using factor IX replacement therapy.
This study tests a medicine called emicizumab, given as a shot under the skin, to see how well it works in children with hemophilia A. It may help prevent bleeding episodes and improve quality of life.
Hear when a new Factor VIII Deficiency, Congenital trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.